A novo alzheimer's trial has been disappointing, while amycretin has shown promise. The outcome of this trial is not specified, but it may be related to broader research into the causes of alzheimer's and other brain disorders. Other recent developments in medical research include studies on various diseases and potential treatments, but their connection to the novo alzheimer's trial is unclear.